TY - JOUR
T1 - Methotrexate decreases hippocampal cell proliferation and induces memory deficits in rats
AU - Seigers, Riejanne
AU - Schagen, Sanne B
AU - Coppens, Caroline M
AU - van der Most, Peter J
AU - van Dam, Frits SAM
AU - Koolhaas, Jaap M
AU - Buwalda, Bauke
PY - 2009/8/12
Y1 - 2009/8/12
N2 - Methotrexate (MTX) is a cytostatic agent used in adjuvant chemotherapy for treatment of breast cancer and is associated with cognitive impairment in a subgroup of patients. The aim of this paper is to test whether MTX can rapidly affect various brain structures resulting in decreased hippocampal cell proliferation and white matter damage. We also studied whether cell death occurs in the hippocampus following MTX. All these processes may contribute to the memory deficits reported in patients. The first study explored the effect of an intravenously injected high-dose MTX (250 mg/kg) on hippocampal cell proliferation, white matter, and cell death. Proliferation was not significantly decreased 1 day after administration of MTX, although a high individual variation was seen. However, 7 days after MTX treatment hippocampal cell proliferation was significantly lower compared to control animals. White matter density was decreased in the lateral corpus callosum of animals treated with MTX, 1 day, 1 week, and 3 weeks after treatment. MTX did not induce hippocampal cell death at any of the time intervals after treatment. The second study examined the effect of MTX on memory by subjecting animals to a learning task directly followed with MTX treatment. In both learning tasks, memory was impaired in treated animals. In the Morris water maze, animals treated with MTX spent significantly less time in the correct quadrant compared to control animals during the probe trial which was performed 1 week after training and treatment. In contextual fear conditioning, animals treated with MTX showed significantly less freezing behavior compared to control animals, 4 weeks after training and treatment. These studies suggest that the negative effect of MTX on hippocampal cell proliferation and white matter density may be part of the mechanisms underlying the cognitive impairment observed as side effect after cytotoxic treatment in humans. © 2009 Elsevier B.V. All rights reserved.
AB - Methotrexate (MTX) is a cytostatic agent used in adjuvant chemotherapy for treatment of breast cancer and is associated with cognitive impairment in a subgroup of patients. The aim of this paper is to test whether MTX can rapidly affect various brain structures resulting in decreased hippocampal cell proliferation and white matter damage. We also studied whether cell death occurs in the hippocampus following MTX. All these processes may contribute to the memory deficits reported in patients. The first study explored the effect of an intravenously injected high-dose MTX (250 mg/kg) on hippocampal cell proliferation, white matter, and cell death. Proliferation was not significantly decreased 1 day after administration of MTX, although a high individual variation was seen. However, 7 days after MTX treatment hippocampal cell proliferation was significantly lower compared to control animals. White matter density was decreased in the lateral corpus callosum of animals treated with MTX, 1 day, 1 week, and 3 weeks after treatment. MTX did not induce hippocampal cell death at any of the time intervals after treatment. The second study examined the effect of MTX on memory by subjecting animals to a learning task directly followed with MTX treatment. In both learning tasks, memory was impaired in treated animals. In the Morris water maze, animals treated with MTX spent significantly less time in the correct quadrant compared to control animals during the probe trial which was performed 1 week after training and treatment. In contextual fear conditioning, animals treated with MTX showed significantly less freezing behavior compared to control animals, 4 weeks after training and treatment. These studies suggest that the negative effect of MTX on hippocampal cell proliferation and white matter density may be part of the mechanisms underlying the cognitive impairment observed as side effect after cytotoxic treatment in humans. © 2009 Elsevier B.V. All rights reserved.
KW - analysis of variance
KW - animals
KW - antimetabolites, antineoplastic/pharmacology
KW - association learning/physiology
KW - cell death/drug effects
KW - cell proliferation/drug effects
KW - cognition disorders/chemically induced
KW - cognition/drug effects
KW - conditioning, classical/drug effects
KW - disease models, animal
KW - fear
KW - follow-up studies
KW - hippocampal cell proliferation
KW - hippocampus/cytology
KW - maze learning/drug effects
KW - memory problems
KW - methotrexate/pharmacology
KW - rats, wistar
KW - time factors
KW - angst
KW - antimetabolieten, antineoplastisch/farmacologie
KW - associatief leren/fysiologie
KW - celdood/medicijneffecten
KW - celproliferatie/medicijneffecten
KW - cognitie/medicijneffecten
KW - cognitieve stoornissen/chemisch geïnduceerd
KW - conditionering, klassieke/drugseffecten
KW - dieren
KW - doolhof leren/medicijneffecten
KW - follow-up studies
KW - geheugen problemen
KW - hippocampale celproliferatie
KW - hippocampus/cytologie
KW - methotrexaat/farmacologie
KW - ratten, wistar
KW - tijdsfactoren
KW - variantieanalyse
KW - ziektemodellen, dier
U2 - 10.1016/j.bbr.2009.02.025
DO - 10.1016/j.bbr.2009.02.025
M3 - Article
C2 - 19428645
SN - 0166-4328
VL - 201
SP - 279
EP - 284
JO - Behavioural Brain Research
JF - Behavioural Brain Research
IS - 2
ER -